This article is more than 5 years old. Information may no longer be current.
ChemomAb doses first patient in phase 1 NAFLD trial
Click Here to Manage Email Alerts
ChemomAb dosed the first patient in a phase 1b repeated-dose clinical trial of CM-101 for treating patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, according to a press release.
CM-101 was designed to target the chemokine CCL24, an important driver of fibrotic processes in the liver.
“The initiation of this clinical trial represents an important step forward in the company’s goal to evaluate the potential of CM-101 to interfere with the progression of NASH and its precursor, NAFLD,” Adi Mor, CEO of ChemomAb, said in the release.
The randomized control phase 1b trial was designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CM-101 in patients with fatty liver disease. The trial will comprise 12 weeks of dosing.
“The understanding that CCL24 plays a pivotal role in fibrotic and inflammatory diseases paves the way for assessing CM-101, a first-in-class CCL24 neutralizing antibody, in several unmet need fibrotic indications, NASH being one of them,” Mor said in the release. “We are eager to advance the clinical program with CM-101 in NASH as well as in the orphan indications primary sclerosing cholangitis and systemic sclerosis.”
Reference: www.chemomab.com